PMID- 24516518
OWN - NLM
STAT- MEDLINE
DCOM- 20150522
LR  - 20211021
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 9
IP  - 2
DP  - 2014
TI  - ERG rearrangement is associated with prostate cancer-related death in Chinese 
      prostate cancer patients.
PG  - e84959
LID - 10.1371/journal.pone.0084959 [doi]
LID - e84959
AB  - Recently, ETS-related gene (ERG) gene rearrangements, phosphatase tensin 
      homologue (PTEN) deletions and EGFR family aberrations were characterized as 
      potential biomarkers for prostate cancer (PCa) patient management. Although ERG 
      gene rearrangement has been identified in approximately 50% of localized prostate 
      cancers in western countries, the prognostic significance of this critical 
      molecular event remains unknown in Chinese patients. Using fluorescence in situ 
      hybridization (FISH) and immunohistochemistry, we evaluated ERG, PTEN and EGFR 
      family aberrations in a cohort of 224 Chinese prostate cancer patients diagnosed 
      in transurethral resection of the prostate (TUR-P). Overall, ERG rearrangement 
      was detected in 23.2% (44/190) cases, of which 54.5% (24/44) showed deletion of 
      the 5'end of ERG. PTEN deletion was identified in 10.8% (19/176) cases. 
      Amplification of EGFR and HER2 genes was present in 1.1% (2/178) and 5.8% 
      (10/173) of cases, respectively. Significant correlation between ERG 
      rearrangement and PTEN deletion was identified in this cohort. EGFR and HER2 
      aberrations occurred more frequently in PCas without ERG rearrangement than in 
      those with ERG rearrangement, although this did not reach statistical 
      significance. Overall, ERG rearrangement was associated with pre-operative PSA 
      values (P = 0.038) and cancer-related death (P = 0.02), but not with the age, 
      clinical T stage, Gleason score, or Ki-67 labeling index (LI). Notably, 
      multivariate analysis including known prognostic markers revealed ERG 
      rearrangement was an independent prognostic factor (P = 0.022). Additionally, ERG 
      rearrangement status was helpful to identify patients with poor prognosis from 
      PCa group with low Ki-67 LI. In summary, we reported that ERG rearrangement was 
      associated with cancer-related death in Chinese PCa patients. Determination of 
      ERG rearrangement status allows stratification of PCa patients into different 
      survival categories.
FAU - Qi, Mei
AU  - Qi M
AD  - Department of Pathology, Shandong University Medical School, Jinan, China.
FAU - Yang, Xiaoqing
AU  - Yang X
AD  - Department of Pathology, Shandong University Medical School, Jinan, China.
FAU - Zhang, Fan
AU  - Zhang F
AD  - Department of Orthodontics, Shandong University School of Stomatology, Jinan, 
      China.
FAU - Lin, Tao
AU  - Lin T
AD  - Department of Surgery, The Central Hospital of Jinan, Jinan, China.
FAU - Sun, Xiubin
AU  - Sun X
AD  - Department of Statistics, Shandong University School of Public Health, Jinan, 
      China.
FAU - Li, Yanjiang
AU  - Li Y
AD  - Department of Urology, The Affiliated Hospital of Qingdao University Medical 
      College, Qingdao, China.
FAU - Yuan, Huiqing
AU  - Yuan H
AD  - Department of Biochemistry, Shandong University Medical School, Jinan, China.
FAU - Ren, Yubo
AU  - Ren Y
AD  - Department of Pathology, Liaocheng General Hospital, Liaocheng, China.
FAU - Zhang, Juan
AU  - Zhang J
AD  - Department of Pathology, Shandong University Qilu hospital, Jinan, China.
FAU - Qin, Xiaomin
AU  - Qin X
AD  - Department of Pathology, Shandong University Qilu hospital, Jinan, China.
FAU - Han, Bo
AU  - Han B
AD  - Department of Pathology, Shandong University Medical School, Jinan, China ; 
      Department of Pathology, Shandong University Qilu hospital, Jinan, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140207
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (ERG protein, mouse)
RN  - 0 (Oncogene Proteins)
RN  - 0 (Transcription Factors)
RN  - 0 (Transcriptional Regulator ERG)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - EC 3.1.3.67 (PTEN Phosphohydrolase)
RN  - EC 3.1.3.67 (PTEN protein, human)
SB  - IM
MH  - Adenocarcinoma/*genetics/mortality/pathology
MH  - Aged
MH  - China
MH  - ErbB Receptors/genetics/metabolism
MH  - Gene Rearrangement
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Oncogene Proteins/*genetics/metabolism
MH  - PTEN Phosphohydrolase/genetics/metabolism
MH  - Prognosis
MH  - Prostatic Neoplasms/*genetics/mortality/pathology
MH  - Survival Rate
MH  - Transcription Factors/*genetics/metabolism
MH  - Transcriptional Regulator ERG
PMC - PMC3917829
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2014/02/12 06:00
MHDA- 2015/05/23 06:00
PMCR- 2014/02/07
CRDT- 2014/02/12 06:00
PHST- 2013/08/15 00:00 [received]
PHST- 2013/11/20 00:00 [accepted]
PHST- 2014/02/12 06:00 [entrez]
PHST- 2014/02/12 06:00 [pubmed]
PHST- 2015/05/23 06:00 [medline]
PHST- 2014/02/07 00:00 [pmc-release]
AID - PONE-D-13-33701 [pii]
AID - 10.1371/journal.pone.0084959 [doi]
PST - epublish
SO  - PLoS One. 2014 Feb 7;9(2):e84959. doi: 10.1371/journal.pone.0084959. eCollection 
      2014.